Diamyd   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Stockholm Sweden (1994)

Organization Overview

First Clinical Trial
2004
NCT00456027
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Diamyd Inc | Diamyd Medical AB | Diamyd Therapeutics AB

Active Ingredients

Drugs in Phase 3 Trials (3)

diamyd (8 trials)

rhgad65 (1 trial)

vitamin d3 (6 trials)

Drugs in Phase 2 Trials (6)

alprazolam (1 trial)

etanercept (enbrel) (1 trial)

gad-alum (4 trials)

gamma-aminobutyric acid (1 trial)

ibuprofen (motrin) (1 trial)

np2 (2 trials)

Drugs in Phase 1 Trials (2)

maltodextrin (1 trial)

piperidic acid (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Autoimmune Diseases (Phase 2)

Cancer Pain (Phase 1)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 1 (Phase 3)

Endocrine System Diseases (Phase 2)

Glucose Metabolism Disorders (Phase 2)

Immune System Diseases (Phase 2)

Latent Autoimmune Diabetes in Adults (Phase 2)

Metabolic Diseases (Phase 2)

Pain, Intractable (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 16
  • # of Trial APIs: 11